Revealed: 1 Marijuana Stock I Like More Than Aurora Cannabis (TSX:ACB)

Fire & Flower Holdings Inc. (TSXV:FAF) is one cannabis penny stock that could make you filthy rich.

| More on:
Powder of Cannabis (Drugs), Analysis of Cannabis in laboratory.

Image source: Getty Images

In prior pieces, I’ve highlighted several reasons why Aurora Cannabis was one of my preferred picks in the highly speculative marijuana market. Aurora was growing tonnes of weed in a somewhat efficient manner, which is how a firm can succeed in a commoditized market.

Although you could make a quick buck from betting on cannabis cultivators, I’d much prefer owning shares of a company that’s able to differentiate itself in some form or another. As a grower and distributor of weed, there isn’t much wiggle room to promote brand differentiation with all the regulations that are in place.

Aurora Cannabis and many other pot firms have hovered in the grey area in the past with the hopes of making a name for themselves through the promotion of music festivals. As Health Canada cracks down on the rule breakers, however, every firm’s compliance will be heightened, making it nearly impossible to garner brand loyalty.

How can a cannabis company differentiate itself with all that red tape?

It’s simple: don’t be a cannabis producer, and you won’t be subject to the regulations that seek to make product differentiation next to impossible.

Fire & Flower Holdings (TSXV:FAF), an Edmonton-based cannabis retailer, recently caught my attention after Alimentation Couche-Tard announced its 9.9% stake in the company with the option to own a controlling stake in the firm should it choose to.

Fire & Flower is a marijuana penny stock with a market cap of just $160 million. Shares trade for $1.35, and although I’ve urged Foolish investors to avoid penny stocks like the plague, I think Fire & Flower is a rare exception. It’s a legitimate play that likely has a risk/reward trade-off that favours the investor.

The cannabis retailer has only 23 cannabis shops across the prairies and Ontario. Although it’s tough to trust the management team of a firm that’s as small as Fire & Flower, I am encouraged by all the good things that CEO Brian Hannasch had to say about the management and its expertise in physical and digital cannabis retail.

Moreover, one can’t help but notice how gorgeous the Fire & Flower store layout is. It’s like the Apple store of weed. And although such an arrangement can easily be replicated by some other micro-cap up-and-comer, I think Fire & Flower can keep competitors at bay thanks to the involvement of Couche-Tard and its deep pockets, which will help the company scale up faster than its less-capitalized peers.

Couche-Tard has a brilliant management team that’s been delivering market-crushing results for investors over the years. They’re prudent when it comes to M&A, and it’s going to be no different with Couche-Tard’s initial investment in the world of cannabis.

Hannasch and company clearly see something in Fire & Flower, and it’s not hard to see why. The company has a robust online presence and ample room for an ambitious national expansion. Although Couche-Tard’s initial investment is just a toe in the waters, I think Fire & Flower may be scooped up entirely in a few years’ time should things go smoothly.

In any case, Fire & Flower is a sound investment — not a speculation, despite being in deep penny-stock territory.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette owns shares of ALIMENTATION COUCHE-TARD INC and Apple. David Gardner owns shares of Apple. The Motley Fool owns shares of Apple and has the following options: short January 2020 $155 calls on Apple, long January 2020 $150 calls on Apple, short January 2020 $155 calls on Apple, and long January 2020 $150 calls on Apple. Couche-Tard is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »